

Position statement on the prescribing of Perindopril Arginine

Following the NHS England guidance 'Items which should not routinely be prescribed in primary care: Guidance for CCGs (version 2, June 2019) the following changes to prescribing have been agreed across Barking and Dagenham, Havering and Redbridge.

**From 17th September 2019
Barking and Dagenham, Havering and Redbridge Clinical
Commissioning Groups (BHR CCGs) no longer supports the
prescribing of Perindopril Arginine**

Decision

- The decision to stop Perindopril Arginine applies to ALL patients across Barking and Dagenham, Havering and Redbridge. BHR CCGs have agreed NO exceptions to this recommendation

Please note that other perindopril salt formulations remain available to be prescribed i.e. Perindopril erbumine

This decision was made because:

- A [PrescQIPP Community Interest Company \(CIC\) review](#) of Perindopril Arginine salt versus Perindopril erbumine salt found there was no clinical advantage of the arginine salt. Perindopril Arginine is significantly more expensive than Perindopril Erbumine
- BHR CCGs have a duty to spend taxpayer's money wisely, to make sure they get the best value possible – especially when NHS funding is being severely squeezed and more patients are being seen with more complex health issues than ever before

Reference:

NHS England and NHS Improvement. Items which should not routinely be prescribed in primary care: Guidance for CCGs. Version 2, June 2019. Publishing approval reference 000608 <https://www.england.nhs.uk/publication/items-which-should-not-be-routinely-prescribed-in-primary-care-guidance-for-ccgs/>